CLAIMS:

1. An immunoconjugate comprising an antibody covalently attached to one or more 8-Cyc-2-aminobenzazepine moieties by a linker, and having Formula I:

$$Ab–[L–CycBz]_p \qquad I$$


or a pharmaceutically acceptable salt thereof,

wherein:

Ab is an antibody construct that has an antigen binding domain that binds PD-L1;

p is an integer from 1 to 8;

CycBz is the 8-Cyc-2-aminobenzazepine moiety having the formula:




Cyc is selected from the group consisting of phenyldiyl, heterocyclyldiyl and heteroaryldiyl;

$R^1$, $R^2$, $R^3$, and $R^4$ are independently selected from the group consisting of H, $C_1$-$C_{12}$ alkyl, $C_2$-$C_6$ alkenyl, $C_2$-$C_6$ alkynyl, $C_3$-$C_{12}$ carbocyclyl, $C_6$-$C_{20}$ aryl, $C_2$-$C_9$ heterocyclyl, and $C_1$-$C_{20}$ heteroaryl, where alkyl, alkenyl, alkynyl, carbocyclyl, aryl, heterocyclyl, and heteroaryl are independently and optionally substituted with one or more groups selected from:

–($C_1$-$C_{12}$ alkyldiyl)–N($R^5$)–*;

–($C_1$-$C_{12}$ alkyldiyl)–N($R^5$)$_2$;

–($C_1$-$C_{12}$ alkyldiyl)–O$R^5$;

–($C_3$-$C_{12}$ carbocyclyl);

–($C_3$-$C_{12}$ carbocyclyl)–*;

–($C_3$-$C_{12}$ carbocyclyl)–($C_1$-$C_{12}$ alkyldiyl)–N$R^5$–*;

–($C_3$-$C_{12}$ carbocyclyl)–($C_1$-$C_{12}$ alkyldiyl)–N($R^5$)$_2$;

–($C_3$-$C_{12}$ carbocyclyl)–N$R^5$–C(=N$R^5$)N$R^5$–*;

–($C_6$-$C_{20}$ aryl);

–($C_6$-$C_{20}$ aryldiyl)–*;

–($C_6$-$C_{20}$ aryldiyl)–N($R^5$)–*;

–($C_6$-$C_{20}$ aryldiyl)–($C_1$-$C_{12}$ alkyldiyl)–N($R^5$)–*;

–($C_6$-$C_{20}$ aryldiyl)–($C_1$-$C_{12}$ alkyldiyl)–($C_2$-$C_{20}$ heterocyclyldiyl)–*;

–($C_6$-$C_{20}$ aryldiyl)–($C_1$-$C_{12}$ alkyldiyl)–N($R^5$)$_2$;

–($C_6$-$C_{20}$ aryldiyl)–($C_1$-$C_{12}$ alkyldiyl)–N$R^5$–C(=N$R^{5a}$)N($R^5$)–*;

–($C_2$-$C_{20}$ heterocyclyl);

–($C_2$-$C_{20}$ heterocyclyl)–*;

–($C_2$-$C_9$ heterocyclyl)–($C_1$-$C_{12}$ alkyldiyl)–N$R^5$–*;

–($C_2$-$C_9$ heterocyclyl)–($C_1$-$C_{12}$ alkyldiyl)–N($R^5$)$_2$;

–($C_2$-$C_9$ heterocyclyl)–C(=O)–($C_1$-$C_{12}$ alkyldiyl)–N($R^5$)–*;

–($C_2$-$C_9$ heterocyclyl)–N$R^5$–C(=N$R^{5a}$)N$R^5$–*;

–($C_2$-$C_9$ heterocyclyl)–N$R^5$–($C_6$-$C_{20}$ aryldiyl)–($C_1$-$C_{12}$ alkyldiyl)–N($R^5$)–*;

–($C_2$-$C_9$ heterocyclyl)–($C_6$-$C_{20}$ aryldiyl)–*;

–($C_1$-$C_{20}$ heteroaryl);

–($C_1$-$C_{20}$ heteroaryl)–*;

–($C_1$-$C_{20}$ heteroaryl)–($C_1$-$C_{12}$ alkyldiyl)–N($R^5$)–*;

–($C_1$-$C_{20}$ heteroaryl)–($C_1$-$C_{12}$ alkyldiyl)–N($R^5$)$_2$;

–($C_1$-$C_{20}$ heteroaryl)–N$R^5$–C(=N$R^{5a}$)N($R^5$)–*;

–($C_1$-$C_{20}$ heteroaryl)–N($R^5$)C(=O)–($C_1$-$C_{12}$ alkyldiyl)–N($R^5$)–*;

–C(=O)–*;

–C(=O)–($C_1$-$C_{12}$ alkyldiyl)–N($R^5$)–*;

–C(=O)–($C_2$-$C_{20}$ heterocyclyldiyl)–*;

–C(=O)N($R^5$)$_2$;

–C(=O)N($R^5$)–*;

–C(=O)N($R^5$)–($C_1$-$C_{12}$ alkyldiyl)–N($R^5$)C(=O)$R^5$;

–C(=O)N($R^5$)–($C_1$-$C_{12}$ alkyldiyl)–N($R^5$)C(=O)N($R^5$)$_2$;

–C(=O)N$R^5$–($C_1$-$C_{12}$ alkyldiyl)–N($R^5$)C$O_2R^5$;

–C(=O)N$R^5$–($C_1$-$C_{12}$ alkyldiyl)–N($R^5$)C(=N$R^{5a}$)N($R^5$)$_2$;

–C(=O)N$R^5$–($C_1$-$C_{12}$ alkyldiyl)–N$R^5$C(=N$R^{5a}$)$R^5$;

–C(=O)N$R^5$–($C_1$-$C_8$ alkyldiyl)–N$R^5$($C_2$-$C_5$ heteroaryl);

–C(=O)N$R^5$–($C_1$-$C_{20}$ heteroaryldiyl)–N($R^5$)–*;

–C(=O)N$R^5$–($C_1$-$C_{20}$ heteroaryldiyl)–*;

–C(=O)N$R^5$–($C_1$-$C_{20}$ heteroaryldiyl)–($C_1$-$C_{12}$ alkyldiyl)–N($R^5$)$_2$;

–C(=O)NR$^5$–(C$_1$-C$_{20}$ heteroaryldiyl)–(C$_2$-C$_{20}$ heterocyclyldiyl)–C(=O)NR$^5$–(C$_1$-C$_{12}$ alkyldiyl)–NR$^5$–*;

–N(R$^5$)$_2$;

–N(R$^5$)–*;

–N(R$^5$)C(=O)R$^5$;

–N(R$^5$)C(=O)–*;

–N(R$^5$)C(=O)N(R$^5$)$_2$;

–N(R$^5$)C(=O)N(R$^5$)–*;

–N(R$^5$)CO$_2$R$^5$;

–NR$^5$C(=NR$^{5a}$)N(R$^5$)$_2$;

–NR$^5$C(=NR$^{5a}$)N(R$^5$)–*;

–NR$^5$C(=NR$^{5a}$)R$^5$;

–N(R$^5$)C(=O)–(C$_1$-C$_{12}$ alkyldiyl)–N(R$^5$)–*;

–N(R$^5$)–(C$_2$-C$_5$ heteroaryl);

–N(R$^5$)–S(=O)$_2$–(C$_1$-C$_{12}$ alkyl);

–O–(C$_1$-C$_{12}$ alkyl);

–O–(C$_1$-C$_{12}$ alkyldiyl)–N(R$^5$)$_2$;

–O–(C$_1$-C$_{12}$ alkyldiyl)–N(R$^5$)–*;

–O–C(=O)N(R$^5$)$_2$;

–O–C(=O)N(R$^5$)–*;

–S(=O)$_2$–(C$_2$-C$_{20}$ heterocyclyldiyl)–*;

–S(=O)$_2$–(C$_2$-C$_{20}$ heterocyclyldiyl)–(C$_1$-C$_{12}$ alkyldiyl)–N(R$^5$)$_2$;

–S(=O)$_2$–(C$_2$-C$_{20}$ heterocyclyldiyl)–(C$_1$-C$_{12}$ alkyldiyl)–NR$^5$–*; and

–S(=O)$_2$–(C$_2$-C$_{20}$ heterocyclyldiyl)–(C$_1$-C$_{12}$ alkyldiyl)–OH;

or R$^2$ and R$^3$ together form a 5- or 6-membered heterocyclyl ring;

X$^1$, X$^2$, X$^3$, and X$^4$ are independently selected from the group consisting of a bond, C(=O), C(=O)N(R$^5$), O, N(R$^5$), S, S(O)$_2$, and S(O)$_2$N(R$^5$);

R$^5$ is independently selected from the group consisting of H, C$_6$-C$_{20}$ aryl, C$_3$-C$_{12}$ carbocyclyl, C$_6$-C$_{20}$ aryldiyl, C$_1$-C$_{12}$ alkyl, and C$_1$-C$_{12}$ alkyldiyl, or two R$^5$ groups together form a 5- or 6-membered heterocyclyl ring;

R$^{5a}$ is selected from the group consisting of C$_6$-C$_{20}$ aryl and C$_1$-C$_{20}$ heteroaryl;

where the asterisk * indicates the attachment site of L, and where one of R$^1$, R$^2$, R$^3$ and R$^4$ is attached to L;

L is the linker selected from the group consisting of:

–C(=O)–PEG–;

–C(=O)–PEG–C(=O)N($R^6$)–($C_1$-$C_{12}$ alkyldiyl)–C(=O)–Gluc–;

–C(=O)–PEG–O–;

–C(=O)–PEG–O–C(=O)–;

–C(=O)–PEG–C(=O)–;

–C(=O)–PEG–C(=O)–PEP–;

–C(=O)–PEG–N($R^6$)–;

–C(=O)–PEG–N($R^6$)–C(=O)–;

–C(=O)–PEG–N($R^6$)–PEG–C(=O)–PEP–;

–C(=O)–PEG–$N^+$($R^6$)$_2$–PEG–C(=O)–PEP–;

–C(=O)–PEG–C(=O)–PEP–N($R^6$)–($C_1$-$C_{12}$ alkyldiyl)–;

–C(=O)–PEG–C(=O)–PEP–N($R^6$)–($C_1$-$C_{12}$ alkyldiyl)N($R^6$)C(=O)–($C_2$-$C_5$ monoheterocyclyldiyl)–;

–C(=O)–PEG–SS–($C_1$-$C_{12}$ alkyldiyl)–OC(=O)–;

–C(=O)–PEG–SS–($C_1$-$C_{12}$ alkyldiyl)–C(=O)–;

–C(=O)–($C_1$-$C_{12}$ alkyldiyl)–C(=O)–PEP–;

–C(=O)–($C_1$-$C_{12}$ alkyldiyl)–C(=O)–PEP–N($R^6$)–($C_1$-$C_{12}$ alkyldiyl)–;

–C(=O)–($C_1$-$C_{12}$ alkyldiyl)–C(=O)–PEP–N($R^6$)–($C_1$-$C_{12}$ alkyldiyl)–N($R^5$)–C(=O);

–C(=O)–($C_1$-$C_{12}$ alkyldiyl)–C(=O)–PEP–N($R^6$)–($C_1$-$C_{12}$ alkyldiyl)–N($R^6$)C(=O)–($C_2$-$C_5$ monoheterocyclyldiyl)–;

–succinimidyl–($CH_2$)$_m$–C(=O)N($R^6$)–PEG–;

–succinimidyl–($CH_2$)$_m$–C(=O)N($R^6$)–PEG–C(=O)N($R^6$)–($C_1$-$C_{12}$ alkyldiyl)–C(=O)–Gluc–;

–succinimidyl–($CH_2$)$_m$–C(=O)N($R^6$)–PEG–O–;

–succinimidyl–($CH_2$)$_m$–C(=O)N($R^6$)–PEG–O–C(=O)–;

–succinimidyl–($CH_2$)$_m$–C(=O)N($R^6$)–PEG–C(=O)–;

–succinimidyl–($CH_2$)$_m$–C(=O)N($R^6$)–PEG–N($R^5$)–;

–succinimidyl–($CH_2$)$_m$–C(=O)N($R^6$)–PEG–N($R^5$)–C(=O)–;

–succinimidyl–($CH_2$)$_m$–C(=O)N($R^6$)–PEG–C(=O)–PEP–;

–succinimidyl–($CH_2$)$_m$–C(=O)N($R^6$)–PEG–SS–($C_1$-$C_{12}$ alkyldiyl)–OC(=O)–;

–succinimidyl–($CH_2$)$_m$–C(=O)–PEP–N($R^6$)–($C_1$-$C_{12}$ alkyldiyl)–;


–succinimidyl–$(CH_2)_m$–C(=O)–PEP–N($R^6$)–($C_1$-$C_{12}$ alkyldiyl)N($R^6$)C(=O)–; and

–succinimidyl–$(CH_2)_m$–C(=O)–PEP–N($R^6$)–($C_1$-$C_{12}$ alkyldiyl)N($R^6$)C(=O)–($C_2$-$C_5$ monoheterocyclyldiyl)–;

$R^6$ is independently H or $C_1$-$C_6$ alkyl;


PEG has the formula: $–(CH_2CH_2O)_n–(CH_2)_m–$; m is an integer from 1 to 5, and n is an integer from 2 to 50;

Gluc has the formula:




;

PEP has the formula:



where AA is independently selected from a natural or unnatural amino acid side chain, or one or more of AA, and an adjacent nitrogen atom form a 5-membered ring proline amino acid, and the wavy line indicates a point of attachment;

Cyc is selected from $C_6$-$C_{20}$ aryldiyl and $C_1$-$C_{20}$ heteroaryldiyl, optionally substituted with one or more groups selected from F, Cl, $NO_2$, –OH, $–OCH_3$, and a glucuronic acid having the structure:



;

$R^7$ is selected from the group consisting of $–CH(R^8)O–$, $–CH_2–$, $–CH_2N(R^8)–$, and $–CH(R^8)O–C(=O)–$, where $R^8$ is selected from H, $C_1$-$C_6$ alkyl, $C(=O)–C_1$-$C_6$ alkyl, and $–C(=O)N(R^9)_2$, where $R^9$ is independently selected from the group consisting of H, $C_1$-$C_{12}$ alkyl, and $–(CH_2CH_2O)_n–(CH_2)_m–OH$, where m is an integer from 1 to 5, and n is an integer from 2 to 50, or two $R^9$ groups together form a 5- or 6-membered heterocyclyl ring;

y is an integer from 2 to 12;

z is 0 or 1; and

alkyl, alkyldiyl, alkenyl, alkenyldiyl, alkynyl, alkynyldiyl, aryl, aryldiyl, carbocyclyl, carbocyclyldiyl, heterocyclyl, heterocyclyldiyl, heteroaryl, and heteroaryldiyl are independently and optionally substituted with one or more groups independently selected from F, Cl, Br, I, –CN, $–CH_3$, $–CH_2CH_3$, $–CH=CH_2$, $–C≡CH$, $–C≡CCH_3$, $–CH_2CH_2CH_3$, $–CH(CH_3)_2$, $–CH_2CH(CH_3)_2$, $–CH_2OH$, $–CH_2OCH_3$, $–CH_2CH_2OH$, $–C(CH_3)_2OH$, $–CH(OH)CH(CH_3)_2$, $–C(CH_3)_2CH_2OH$, $–CH_2CH_2SO_2CH_3$, $–CH_2OP(O)(OH)_2$, $–CH_2F$, $–CHF_2$, $–CF_3$, $–CH_2CF_3$, $–CH_2CHF_2$, $–CH(CH_3)CN$, $–C(CH_3)_2CN$, $–CH_2CN$, $–CH_2NH_2$, $–CH_2NHSO_2CH_3$, $–CH_2NHCH_3$, $–CH_2N(CH_3)_2$, $–CO_2H$, $–COCH_3$, $–CO_2CH_3$, $–CO_2C(CH_3)_3$, $–COCH(OH)CH_3$, $–CONH_2$, $–CONHCH_3$, $–CON(CH_3)_2$, $–C(CH_3)_2CONH_2$, $–NH_2$, $–NHCH_3$, $–N(CH_3)_2$, $–NHCOCH_3$, $–N(CH_3)COCH_3$, $–NHS(O)_2CH_3$, $–N(CH_3)C(CH_3)_2CONH_2$, $–N(CH_3)CH_2CH_2S(O)_2CH_3$, –NHC(=NH)H, $–NHC(=NH)CH_3$, $–NHC(=NH)NH_2$, $–NHC(=O)NH_2$, $–NO_2$, =O, –OH, $–OCH_3$, $–OCH_2CH_3$, $–OCH_2CH_2OCH_3$, $–OCH_2CH_2OH$, $–OCH_2CH_2N(CH_3)_2$, $–O(CH_2CH_2O)_n–(CH_2)_mCO_2H$, $–O(CH_2CH_2O)_nH$, $–OCH_2F$, $–OCHF_2$, $–OCF_3$, $–OP(O)(OH)_2$, $–S(O)_2N(CH_3)_2$, $–SCH_3$, $–S(O)_2CH_3$, and $–S(O)_3H$.

2. The immunoconjugate of claim 1 wherein the antibody is selected from the group consisting of atezolizumab, durvalumab, and avelumab.

3. The immunoconjugate of claim 1 wherein the antibody construct is a Type A PD-L1 antibody and comprises an immunoglobulin heavy chain variable region polypeptide and an immunoglobulin light chain variable region polypeptide, wherein:

the immunoglobulin heavy chain variable region polypeptide comprises a complementarity determining region 1 (HCDR1) comprising any one of Type A SEQ ID NOs: 1-23, a complementarity determining region 2 (HCDR2) comprising any one of SEQ ID NOs: 24-57, and a complementarity determining region 3 (HCDR3) comprising any one of SEQ ID NOs: 58-95; or

the immunoglobulin light chain variable region polypeptide comprises a complementarity determining region 1 (LCDR1) comprising any one of SEQ ID NOs: 96-128, a complementarity determining region 2 (LCDR2) comprising any one of SEQ ID NOs: 129-151, and a complementarity determining region 3 (LCDR3) comprising any one of SEQ ID NOs: 152-155.

4. The immunoconjugate of claim 1 wherein the antibody construct is a Type A PD-L1 antibody and comprises an immunoglobulin heavy chain variable region of any one of SEQ ID NOs: 223-264 or at least the CDRs thereof; and an immunoglobulin light chain variable region of any one of SEQ ID NOs: 265-306 or at least the CDRs thereof;

or comprises an immunoglobulin heavy chain variable region polypeptide with an amino acid sequence that is at least 90% identical to any one of SEQ ID NOs: 223-264, and an immunoglobulin light chain variable region polypeptide with an amino acid sequence that is at least 90% identical to any one of SEQ ID NOs: 265-306.

5. The immunoconjugate of claim 1 wherein the antibody construct is a Type A PD-L1 antibody and comprises the heavy and light chain immunoglobulin polypeptides, or at least the CDRs thereof.

6. The immunoconjugate of claim 1 wherein the antibody construct is a Type B PD-L1 antibody and comprises an immunoglobulin heavy chain variable region polypeptide and an immunoglobulin light chain variable region polypeptide, wherein:

the immunoglobulin heavy chain variable region polypeptide comprises a complementarity determining region 1 (HCDR1) comprising any one of SEQ ID NOs: 1-14, a complementarity determining region 2 (HCDR2) comprising any one of SEQ ID NOs: 15-31, and a complementarity determining region 3 (HCDR3) comprising any one of SEQ ID NOs: 32-52; or

the immunoglobulin light chain variable region polypeptide comprises a complementarity determining region 1 (LCDR1) comprising any one of SEQ ID NOs: 53-67, a complementarity determining region 2 (LCDR2) comprising any one of SEQ ID NOs: 68-79, and a complementarity determining region 3 (LCDR3) comprising any one of SEQ ID NOs: 80-91.

7. The immunoconjugate of claim 1 wherein the antibody construct is a Type B PD-L1 antibody and comprises an immunoglobulin heavy chain variable region of any one of SEQ ID NOs: 123-143 or at least the CDRs thereof; and an immunoglobulin light chain variable region of any one of SEQ ID NOs: 144-164 or at least the CDRs thereof;

or comprises an immunoglobulin heavy chain variable region polypeptide with an amino acid sequence that is at least 90% identical to any one of SEQ ID NOs: 123-143, and an immunoglobulin light chain variable region polypeptide with an amino acid sequence that is at least 90% identical to any one of SEQ ID NOs: 144-164.

8. The immunoconjugate of any one of claims 1 to 7 wherein $X^1$ is a bond, and $R^1$ is H.

9. The immunoconjugate of any one of claims 1 to 7 wherein $X^2$ is a bond, and $R^2$ is $C_1$-$C_8$ alkyl.

10. The immunoconjugate of any one of claims 1 to 7 wherein $X^2$ and $X^3$ are each a bond, and $R^2$ and $R^3$ are independently selected from $C_1$-$C_8$ alkyl, –O–($C_1$-$C_{12}$ alkyl), –($C_1$-$C_{12}$

alkyldiyl)–$OR^5$, –($C_1$-$C_8$ alkyldiyl)–$N(R^5)CO_2R^5$, –($C_1$-$C_{12}$ alkyl)–$OC(O)N(R^5)_2$, –O–($C_1$-$C_{12}$ alkyl)–$N(R^5)CO_2R^5$, and –O–($C_1$-$C_{12}$ alkyl)–$OC(O)N(R^5)_2$.

11. The immunoconjugate of claim 10 wherein $R^2$ is $C_1$-$C_8$ alkyl and $R^3$ is –($C_1$-$C_8$ alkyldiyl)–$N(R^5)CO_2R^5$.


12. The immunoconjugate of claim 11 wherein $R^2$ is $–CH_2CH_2CH_3$ and $R^3$ is selected from $–CH_2CH_2CH_2NHCO_2$(t-Bu), $–OCH_2CH_2NHCO_2$(cyclobutyl), and $–CH_2CH_2CH_2NHCO_2$(cyclobutyl).


13. The immunoconjugate of claim 10 wherein $R^2$ and $R^3$ are each independently selected from $–CH_2CH_2CH_3$, $–OCH_2CH_3$, $–OCH_2CF_3$, $–CH_2CH_2CF_3$, $–OCH_2CH_2OH$, and $–CH_2CH_2CH_2OH$.

14. The immunoconjugate of claim 13 wherein $R^2$ and $R^3$ are each $–CH_2CH_2CH_3$.

15. The immunoconjugate of claim 13 wherein $R^2$ is $–CH_2CH_2CH_3$ and $R^3$ is $–OCH_2CH_3$.

16. The immunoconjugate of any one of claims 1 to 7 wherein $X^3$-$R^3$ is selected from the group consisting of:









and




.


17. The immunoconjugate of any one of claims 1 to 7 wherein $X^4$ is a bond, and $R^4$ is H.

18. The immunoconjugate of any one of claims 1 to 7 wherein $R^1$ is attached to L.

19. The immunoconjugate of any one of claims 1 to 7 wherein $R^2$ or $R^3$ is attached to L.

20. The immunoconjugate of claim 19 wherein $X^3$–$R^3$–L is selected from the group consisting of:





where the wavy line indicates the point of attachment to N.


21. The immunoconjugate of any one of claims 1 to 7 wherein L is –C(=O)–PEG– or –C(=O)–PEG–C(=O)–.


22. The immunoconjugate of any one of claims 1 to 7 wherein L is attached to a cysteine thiol of the antibody.


23. The immunoconjugate of any one of claims 1 to 7 wherein for the PEG, m is 1 or 2, and n is an integer from 2 to 10.


24. The immunoconjugate of claim 23 wherein n is 10.

25. The immunoconjugate of any one of claims 1 to 7 wherein L is selected from the structures:










where the wavy line indicates the attachment to $R^5$.

26. The immunoconjugate of any one of claims 1 to 7 having Formula Ia:



Ia.


27. The immunoconjugate of claim 26 wherein $X^4$ is a bond and $R^4$ is H.

28. The immunoconjugate of claim 26 wherein Cyc is selected from the group consisting of pyridyldiyl, pyrimidyldiyl, pyrazolyldiyl, piperazinyldiyl, piperidinyldiyl, and pyrazinyldiyl.


29. The immunoconjugate of claim 26 wherein $X^2$ and $X^3$ are each a bond, and $R^2$ and $R^3$ are independently selected from $C_1$-$C_8$ alkyl, –O–($C_1$-$C_{12}$ alkyl), –($C_1$-$C_{12}$ alkyldiyl)–$OR^5$, –($C_1$-$C_8$ alkyldiyl)–$N(R^5)CO_2R^5$, –($C_1$-$C_{12}$ alkyl)–$OC(O)N(R^5)_2$, –O–($C_1$-$C_{12}$ alkyl)–$N(R^5)CO_2R^5$, and –O–($C_1$-$C_{12}$ alkyl)–$OC(O)N(R^5)_2$.

30. The immunoconjugate of claim 26 wherein $X^2$ is O.


31. The immunoconjugate of claim 26 selected from Formulae Ib-Ii:


Ab
L
N
N
NH2
N
X2—R2
N
X3—R3
O
p


Ib;


Ab
L
N
N
NH2
N
X2—R2
N
X3—R3
O
p


Ic;


Ab
L
N
N
NH2
N
X2—R2
N
X3—R3
O
p


Id;


Ab
L
N
N
NH2
N
X2—R2
N
X3—R3
O
p


Ie;




If;



Ig;




Ih; and




Ii .


32. The immunoconjugate of claim 26 selected from Formulae Ij-In:





Ij;





Ik;




Il;




Im; and




In .


33. The immunoconjugate of claim 26 wherein $X^2$ and $X^3$ are each a bond, and $R^2$ and $R^3$ are independently selected from $C_1$-$C_8$ alkyl, –O–($C_1$-$C_{12}$ alkyl), –($C_1$-$C_{12}$ alkyldiyl)–$OR^5$, –($C_1$-$C_8$ alkyldiyl)–$N(R^5)CO_2R^5$, and –O–($C_1$-$C_{12}$ alkyl)–$N(R^5)CO_2R^5$.

34. The immunoconjugate of claim 26 wherein $X^2$ and $X^3$ are each a bond, $R^2$ is $C_1$-$C_8$ alkyl, and $R^3$ is selected from –O–($C_1$-$C_{12}$ alkyl) and –O–($C_1$-$C_{12}$ alkyl)–$N(R^5)CO_2R^5$.


35. A 8-Cyc-2-aminobenzazepine-linker compound selected from the group consisting of:




;




;




;




;




;




;




;




;




;




;




;




;




;




;




;




;




;




;




;




;




;




;




;




;




;




;




;




;




;




;




;




;




;




;




;




;



;



; and



.

36. An immunoconjugate prepared by conjugation of an anti PD-L1 antibody with a 8-Cyc-2-aminobenzazepine-linker compound selected from claim 35.

37. A pharmaceutical composition comprising a therapeutically effective amount of an immunoconjugate according to any one of claims 1 to 7, and one or more pharmaceutically acceptable diluent, vehicle, carrier or excipient.

38. Use of an immunoconjugate according to any one of claims 1 to 34 in the manufacture of a medicament for treating cancer, wherein the cancer is selected from cervical cancer, endometrial cancer, ovarian cancer, prostate cancer, pancreatic cancer, esophageal cancer, bladder cancer, urinary tract cancer, urothelial carcinoma, lung cancer, non-small cell lung cancer, Merkel cell carcinoma, colon cancer, colorectal cancer, gastric cancer, and breast cancer.

39. A method of preparing an immunoconjugate of Formula I of claim 1 wherein the 8-Cyc-2-amino-thienoazepine-linker compound of claim 35 is conjugated with the anti PD-L1 antibody.